10-Q: Veru Inc. Q2 2026 Earnings: Focus on Enobosarm and Sabizabulin

Veru Inc. reports Q2 2026 results, highlighting progress in enobosarm and sabizabulin development, while divesting FC2 business and facing ongoing litigation.

Summary

• Veru Inc. reported its financial results for the quarter and six months ended March 31, 2026.
• The company's primary focus remains on the development of enobosarm for obesity and sabizabulin for atherosclerotic cardiovascular disease.
• Significant progress was made in the enobosarm program, with positive results from the Phase 2b QUALITY clinical trial and the initiation of the Phase 2b PLATEAU clinical trial.
• The sabizabulin program is exploring its potential in treating atherosclerotic cardiovascular disease, with a planned Phase 2 dose-finding study.
• The company completed the sale of its FC2 Female Condom business on December 30, 2024, classifying it as discontinued operations.
• Veru Inc. continues to face substantial doubt regarding its ability to continue as a going concern due to its lack of profitability and need for significant future capital.
• The company raised approximately $23.4 million in net proceeds from a public offering of common stock and warrants in October 2025.
• Several legal proceedings, including class action lawsuits and derivative actions, are ongoing.
• Research and development expenses decreased in the current period compared to the prior year, primarily due to reduced personnel and share-based compensation costs.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the significant clinical progress in drug development offset by severe financial concerns and ongoing litigation.

Positives

• Positive topline results from the Phase 2b QUALITY clinical trial for enobosarm, demonstrating statistically significant preservation of lean body mass and dose-dependent greater loss of fat mass when combined with semaglutide.
• Enobosarm treatment in the QUALITY trial showed a statistically significant and clinically meaningful reduction in the proportion of patients experiencing a clinically significant decline in physical function.
• The Phase 2b maintenance extension study for enobosarm showed it can significantly reduce body weight and fat mass regain after discontinuing semaglutide.
• A novel, patentable modified release oral formulation for enobosarm is on track for Phase 3 studies and commercialization, with expected patent expiry in 2046.
• FDA feedback in September 2025 provided regulatory clarity for enobosarm, accepting incremental weight loss as a primary endpoint and confirming 3mg as an acceptable dosage.
• The company initiated the Phase 2b PLATEAU clinical trial for enobosarm in March 2026, focusing on older patients with obesity and a BMI of 35 or higher.
• The sabizabulin program received agreement from the FDA on the unmet medical need for treating atherosclerotic cardiovascular disease and plans a Phase 2 dose-finding study.
• The sale of the FC2 business provided net proceeds of $16.5 million.
• The company raised approximately $23.4 million in net proceeds from a public offering in October 2025.
• Cash, cash equivalents, and restricted cash increased to $27.6 million as of March 31, 2026, from $15.8 million as of September 30, 2025.
• Working capital increased to $28.0 million and stockholders' equity to $34.8 million as of March 31, 2026.

Negatives

• The company continues to have substantial doubt regarding its ability to continue as a going concern due to its lack of profitability and negative cash flow from operations.
• The company estimates its current cash is insufficient to fund its operating, investing, and financing needs for the next twelve months.
• The company has no commercial revenue and may never generate revenue or become profitable.
• The company is subject to multiple ongoing legal proceedings, including class action and derivative lawsuits, with potential for significant financial impact.
• The sale of the FC2 business resulted in a loss on sale of $4.1 million.
• The company recorded a write-off of $870,000 in deferred costs related to the Lincoln Park Purchase Agreement in the three months ended March 31, 2026.
• Research and development expenses were $3.1 million for the three months ended March 31, 2026, and $4.5 million for the six months ended March 31, 2026, indicating continued significant investment without current revenue.

Risks

• The company requires substantial capital to fund its drug development and commercialization efforts, and additional capital may not be available when needed.
• The 'baby shelf' rule may limit the amount of capital the company can raise through primary public offerings in any 12-month period.
• The company's ability to continue as a going concern is uncertain.
• Clinical trial results may not be replicated or may not support marketing approval or commercialization.
• Regulatory authorities may disagree with trial designs or fail to grant approval for products under development.
• The company faces competition from existing and new competitors.
• Intellectual property risks, including the uncertainty of obtaining and enforcing protections, and the possibility of infringing third-party intellectual property.
• Disruptions at regulatory agencies like the FDA could negatively impact the business.
• The company may fail to obtain regulatory approval for or successfully commercialize its products.
• Risks related to the development of its product portfolio, including clinical trials, regulatory approvals, and time/cost to market.
• The company is subject to cybersecurity risks.
• The company may identify material weaknesses or other deficiencies in its internal control over financial reporting in the future.

Future Outlook

The company expects to continue investing significant resources in research and development for its drug candidates. However, it anticipates needing substantial additional capital to fund its operations and development efforts, and there is substantial doubt about its ability to continue as a going concern for the next twelve months. Future capital requirements will depend on various factors, including the success of its financing strategies.

Management Comments

• "Based upon the Companys current operating plan, it estimates that its cash and cash equivalents as of the issuance date of these financial statements are insufficient for the Company to fund operating, investing and financing cash flow needs for the twelve months subsequent to the issuance date of these financial statements."
• "To obtain the capital necessary to fund our operations, we expect to finance our cash needs through public or private equity offerings, debt financing transactions and/or other capital sources."
• "Additional capital may not be available at such times and in such amounts as needed by us to fund our activities on a timely basis."
• "These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve months subsequent to the issuance date of these financial statements."
• "The FDA now guides that incremental weight loss with enobosarm added to GLP-1 RA treatment over the GLP-1 RA treatment alone is an acceptable primary endpoint to support the efficacy of enobosarm for approval."

Industry Context

StockSavvy.ai notes that Veru Inc.'s focus on enobosarm for obesity and sabizabulin for cardiovascular disease aligns with significant unmet needs in these large markets. The company's strategy to leverage GLP-1 RA therapies for obesity with enobosarm for improved body composition and to address residual inflammatory risk in cardiovascular disease with sabizabulin reflects current trends in biopharmaceutical development. However, the company's financial precariousness and reliance on future capital raises significant concerns, a common challenge for clinical-stage biotechs.

Comparison to Industry Standards

• The Phase 2b QUALITY study results for enobosarm in preserving lean mass and increasing fat loss when combined with semaglutide are notable, as typical GLP-1 RA therapy leads to significant lean mass loss. The reported 100% relative reduction in lean mass loss and 42% greater relative loss of fat mass (at 6mg dose) are compelling, though direct comparisons to other SARM-GLP-1 RA combinations are limited as this is a novel approach.
• The development of sabizabulin for atherosclerotic cardiovascular disease follows the recent FDA approval of colchicine for a similar indication. While colchicine demonstrated significant cardiovascular risk reduction, it has safety concerns. Sabizabulin aims to offer a potentially better efficacy and safety profile, positioning it as a next-generation anti-inflammatory therapy in this space.
• The company's ongoing need for substantial capital and the resulting 'going concern' doubt are common among clinical-stage biopharmaceutical companies, especially those with multiple drug candidates in development without current revenue streams. The ability to secure financing is a critical industry-wide challenge.

Legal Proceedings

• A putative class action complaint (Ewing v. Veru Inc., et al.) alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 related to public statements about sabizabulin.
• A derivative action (Maglia v. Steiner et al.) asserts claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment.
• A derivative action (Franchi v. Steiner et al.) asserts claims for breach of fiduciary duty and unjust enrichment.
• A derivative action (Renbarger v. Steiner et al.) asserts claims for breach of fiduciary duty, aiding and abetting, gross mismanagement, waste of corporate assets, and unjust enrichment.
• A derivative action (Alshourbagy v. Steiner et al.) asserts claims for breach of fiduciary duty and contribution.
• A derivative action (Ovadias v. Steiner et al.) asserts claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution.
• The Ewing Lawsuit, Maglia Lawsuit, Franchi Lawsuit, Renbarger Lawsuit, Alshourbagy Lawsuit and the Ovadias Lawsuit are collectively referred to as the Shareholder Litigation.
• Clear Future, Inc. filed a lawsuit (Clear Future, Inc. v. Veru Inc.) alleging breach of representations and warranties in the FC2 Business Sale Purchase Agreement and making claims for fraud, breach of representations and warranties, and a declaratory judgment for indemnification.

Stakeholder Impact

• Shareholders: The ongoing legal proceedings and the company's going concern status create significant uncertainty and potential for dilution if further equity is issued.
• Employees: Reduced personnel costs and share-based compensation expenses may impact employee morale and retention.
• Creditors: The company's ability to continue as a going concern raises concerns for creditors regarding repayment of any outstanding obligations.
• Suppliers: The company's financial situation could impact its ability to meet payment obligations to suppliers.

Next Steps

• Continue development of enobosarm, including advancing the Phase 2b PLATEAU clinical study.
• Explore clinical development of sabizabulin for atherosclerotic cardiovascular disease, starting with a Phase 2 dose-finding proof of concept study.
• Secure additional funding to support operations and development efforts.
• Continue to monitor and manage ongoing legal proceedings.
• Evaluate the impact of adopting new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-11).

Key Dates

Recommendation

Veru Inc. presents a high-risk, high-reward profile. The clinical progress in enobosarm is promising and addresses a significant market need, but the company's severe financial constraints, ongoing litigation, and 'going concern' status introduce substantial uncertainty. A 'hold' recommendation reflects the need for investors to monitor clinical trial outcomes and financing developments closely, while acknowledging the significant risks.

Keywords

Veru Inc., Form 10-Q, Enobosarm, Sabizabulin, Obesity, Cardiovascular Disease, Clinical Trials, FDA, GLP-1 RA, Weight Loss, Muscle Preservation, Inflammation, Biopharmaceutical, SEC Filing